Related Experiment Video
Updated: Aug 10, 2026
11:57
Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice
Published on: July 23, 2017
Advancing Type 1 Diabetes Treatment: 3 PM-Oriented Innovations in Islet Transplantation and Biomaterial Engineering
Fatemeh Sabet Sarvestani1,2, Ramin Yaghobi1, Mohsen Khosravi Maharlooei3
1Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Diabetes/Metabolism Research and Reviews
|August 9, 2026
Summary
Type 1 Diabetes (T1D) management is shifting towards predictive, preventive, and personalized medicine (3 PM). Advances in islet transplantation and biomaterials aim to restore beta-cell function and offer tailored therapies for T1D patients.
Area of Science:
- Immunology
- Endocrinology
- Biomaterials Science
- Regenerative Medicine
Background:
- Type 1 Diabetes (T1D) involves immune destruction of pancreatic beta-cells, leading to insulin deficiency.
- Current T1D therapies manage symptoms but do not restore beta-cell function or halt disease progression.
- Islet transplantation offers a potential cure but faces challenges like immune rejection and donor scarcity.
Purpose of the Study:
- To review recent advances in islet transplantation and biomaterial engineering for T1D.
- To highlight the transition towards a predictive, preventive, and personalized medicine (3 PM) approach for T1D.
- To discuss how new technologies enable tailored therapies for T1D.
Main Methods:
- Review of current literature on T1D therapies, islet transplantation, and biomaterials.
- Exploration of predictive biomarkers, preventive strategies, and personalized interventions.
- Analysis of advancements in biomaterials, encapsulation, and 3D bioprinting for T1D treatment.
Main Results:
- Predictive biomarkers and phenotyping can identify high-risk individuals and forecast graft outcomes.
- Preventive strategies like immunomodulation and bioenergetic support enhance graft tolerance.
- Personalized interventions using biomaterials, encapsulation, and cell replacement address T1D heterogeneity.
Conclusions:
- A paradigm shift towards 3 PM is crucial for T1D management, moving beyond symptom management.
- Biomaterials, encapsulation, and 3D bioprinting are key enablers for implementing 3 PM in T1D.
- Integration of AI and digital health supports predictive control of transplant outcomes for tailored T1D therapy.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...